Despite being China-heavy, AstraZeneca had a superb start to 2020, with Q1 sales CER growth of 17%. While Oncology was once again the key growth driver, reasonable (but possibly transient) support came from ‘Respiratory + Immunology’, and New CVRM. However, a key question is – how long can Astra sustain this momentum, especially when COVID-related forward buying retreats? Moreover, the restoration of healthy group-level operating margins is still missing, thereby making us s
30 Apr 2020
Euphoric Q1 20 sales growth, despite high Chinese exposure
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Euphoric Q1 20 sales growth, despite high Chinese exposure
AstraZeneca PLC (AZN:LON) | 10,689 0 0.0% | Mkt Cap: 165,702m
- Published:
30 Apr 2020 -
Author:
Surbhit Gupta -
Pages:
5
Despite being China-heavy, AstraZeneca had a superb start to 2020, with Q1 sales CER growth of 17%. While Oncology was once again the key growth driver, reasonable (but possibly transient) support came from ‘Respiratory + Immunology’, and New CVRM. However, a key question is – how long can Astra sustain this momentum, especially when COVID-related forward buying retreats? Moreover, the restoration of healthy group-level operating margins is still missing, thereby making us s